Digital twin simulations with a micro-multiphysics agent-based model reveal key drivers of bone loss after denosumab discontinuation
These findings highlight potential targets for managing fracture risk when discontinuing denosumab and emphasize the importance of personalized treatment strategies based on high-resolution imaging in addition to bone turnover marker measurements.
Authors
- Charles Ledoux (ORCID: https://orcid.org/0000-0002-0344-1608)
- Jack J. Kendall (ORCID: https://orcid.org/0000-0002-0500-9261)
- Ralph Müller (ORCID: https://orcid.org/0000-0002-5811-7725)
- Daniele Boaretti (ORCID: https://orcid.org/0000-0001-8411-7465)
- Caitlyn J. Collins
Institutions
- ETH Zurich (CH)
- Institute for Biomedical Engineering (CH)
- Virginia Tech (US)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fbioe.2025.1652201
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00